A citation-based method for searching scientific literature

Lara Petelin, Lucinda Hossack, Gillian Mitchell, Danny Liew, Alison H Trainer, Paul A James. Value Health 2019
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.
Ranjit Manchanda, Li Sun, Shreeya Patel, Olivia Evans, Janneke Wilschut, Ana Carolina De Freitas Lopes, Faiza Gaba, Adam Brentnall, Stephen Duffy, Bin Cui,[...]. Cancers (Basel) 2020
8
100

BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.
Jan Norum, Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Dag Erik Undlien, Ellen Schlichting, Lovise Mæhle. ESMO Open 2018
11
100

A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.
Natalie J Engel, Patricia Gordon, Darcy L Thull, Beth Dudley, Judy Herstine, Rachel C Jankowitz, Kristin K Zorn. Fam Cancer 2012
11
100

Knowledge, attitude and practice of Nigerian women towards breast cancer: a cross-sectional study.
Michael N Okobia, Clareann H Bunker, Friday E Okonofua, Usifo Osime. World J Surg Oncol 2006
134
100

Breast cancer treatment costs in younger, privately insured women.
Benjamin T Allaire, Donatus U Ekwueme, Diana Poehler, Cheryll C Thomas, Gery P Guy, Sujha Subramanian, Justin G Trogdon. Breast Cancer Res Treat 2017
16
100

The Economic Burden of Breast Cancer in Iran.
Rajabali Daroudi, Ali Akbari Sari, Azin Nahvijou, Bita Kalaghchi, Massoomeh Najafi, Kazem Zendehdel. Iran J Public Health 2015
28
100

Cost of breast cancer based on real-world data: a cancer registry study in Italy.
Stefano Capri, Antonio Russo. BMC Health Serv Res 2017
18
100

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. Int J Surg 2010
100

Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis.
Deepa Lalla, Rashad Carlton, Eduardo Santos, Thomas Bramley, Anna D'Souza. Springerplus 2014
9
100


Discounting in Economic Evaluations.
Arthur E Attema, Werner B F Brouwer, Karl Claxton. Pharmacoeconomics 2018
103
100

Cost-effectiveness of testing for breast cancer susceptibility genes.
Margaret L Holland, Alissa Huston, Katia Noyes. Value Health 2009
33
100

A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Yonghong Li, Andre R Arellano, Lance A Bare, Richard A Bender, Charles M Strom, James J Devlin. Value Health 2017
24
100

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Ranjit Manchanda, Shreeya Patel, Antonis C Antoniou, Ephrat Levy-Lahad, Clare Turnbull, D Gareth Evans, John L Hopper, Robert J Macinnis, Usha Menon, Ian Jacobs,[...]. Am J Obstet Gynecol 2017
33
100

A micro costing of NHS cancer genetic services.
G L Griffith, R Tudor-Edwards, J Gray, R Butler, C Wilkinson, J Turner, B France, P Bennett. Br J Cancer 2005
11
100

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Shreeya Patel, Rosa Legood, D Gareth Evans, Clare Turnbull, Antonis C Antoniou, Usha Menon, Ian Jacobs, Ranjit Manchanda. Am J Obstet Gynecol 2018
19
100

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
Elvira D'Andrea, Carolina Marzuillo, Corrado De Vito, Marco Di Marco, Erica Pitini, Maria Rosaria Vacchio, Paolo Villari. Genet Med 2016
44
100

Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Dirk Müller, Marion Danner, Rita Schmutzler, Christoph Engel, Kirsten Wassermann, Björn Stollenwerk, Stephanie Stock, Kerstin Rhiem. Eur J Health Econ 2019
6
100

Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Julia Simoes Correa-Galendi, Maria Del Pilar Estevez Diz, Stephanie Stock, Dirk Müller. Appl Health Econ Health Policy 2021
8
100

Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
Ka Keat Lim, Sook Yee Yoon, Nur Aishah Mohd Taib, Fatiha Hana Shabaruddin, Maznah Dahlui, Yin Ling Woo, Meow Keong Thong, Soo Hwang Teo, Nathorn Chaiyakunapruk. Appl Health Econ Health Policy 2018
5
100

Population Based Testing for Primary Prevention: A Systematic Review.
Ranjit Manchanda, Faiza Gaba. Cancers (Basel) 2018
16
100


Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study.
Xian-Zhen Liao, Ju-Fang Shi, Jing-Shi Liu, Hui-Yao Huang, Lan-Wei Guo, Xin-Yu Zhu, Hai-Fan Xiao, Le Wang, Ya-Na Bai, Guo-Xiang Liu,[...]. Asia Pac J Clin Oncol 2018
17
100

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
Don Husereau, Michael Drummond, Stavros Petrou, Chris Carswell, David Moher, Dan Greenberg, Federico Augustovski, Andrew H Briggs, Josephine Mauskopf, Elizabeth Loder. Cost Eff Resour Alloc 2013
152
100

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
79
100

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side,[...]. J Natl Cancer Inst 2014
100
100

An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
Kathryn A Phillips, David Veenstra, Stephanie Van Bebber, Julie Sakowski. Pharmacogenomics 2003
34
100

Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
Kim De Leeneer, Ilse Coene, Brecht Crombez, Justine Simkens, Rudy Van den Broecke, Alain Bols, Barbara Stragier, Ilse Vanhoutte, Anne De Paepe, Bruce Poppe,[...]. Breast Cancer Res Treat 2012
21
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.